Found 2 articles for: "Afamelanotide"
Into the Light: Afamelanotide and the Treatment of Erythropoietic Protoporphyria in the United States
September 2023 | Volume 22 | Issue 9 | Original Article | 941 | Copyright © September 2023
Background: Erythropoietic protoporphyria (EPP) is a rare disease that causes disabling cutaneous photosensitivity with pain and burning sensations. In 2019, afamelanotide, an &a...
Read MoreAfamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications
March 2021 | Volume 20 | Issue 3 | Original Article | 290 | Copyright © March 2021
Afamelanotide (SCENESSE®) is a synthetic analogue of α‐melanocyte-stimulating hormone that is FDA-approved to increase pain-free sunlight exposure in adult patients with erythro...
Read More
